Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications
Biobank of Data and of Human Biological Samples on Prematurity, Preeclampsia and Other Pregnancy Complications
CHU de Quebec-Universite Laval
7,845 participants
Apr 1, 2015
OBSERVATIONAL
Conditions
Summary
The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.
Eligibility
Inclusion Criteria1
- (specific to each study)
Exclusion Criteria3
- pregnant women \<18 years old at recruitment
- negative fetal heart at recruitment
- women not able to provide an informed consent to the study
Interventions
All women of the biobank have provided: 1. blood samples (plasma, serum and Buffy-coat) 2. urine samples 3. demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history) 4. mean arterial blood pressure 5. ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases) 6. access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02744365